© 1994 by Oxford University Press
Journal of the National Cancer Institute, Vol. 86, No. 16, 1228-1233,
August 17, 1994
© 1994 Oxford University Press
Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus Therapy
*Affiliations of authors: Department of Pathology
Department of Neurosurgery
(Department of Immunology/ Microbiology), Rush-Presbyterian-St. Luke's Medical Center Chicago III
Department of Surgery, Cook Country Hospital and university of Illinois College of Medicine Chicago
Department of Surgery, Cook Country Hospital Chicago
Correspondence to: Robert M. Lorence, M. D., Ph.D., Department of Pathology, Rush-Presbyterian-St. Luke's Medical Center, 1653 W. Congress, Chicago, IL60612-3833.
Background: Neuroblastoma is the most common pediatric extra-cranial solid cancer. Using conventional ther apies, Children older than 1 year of age with advanced neuroblastoma have a poor progrnosis. The development of new approaches for treating such children with neuroblastoma continues to be one of the most important goals today in pediatric oncology. Despite numerous anecdotal reports of human tumor regression during viral infections, the use of viruses to directly lyse neuroblastoma cells has never been reported as a potential therapy.New-castle disease virus(NDV) has been shown to replicate in and kill cultured human and rat neuroblastoma cells but not normal human fibroblasts. Purpose: Our purpose was to determine if this selective killing of human neuroblastoma (IMR-32) cells is maintained during the in vivo treatment of established tumors. Mothods: Two experiments were performed using NDV strain 73-T Athymic mice with subcutaneous IMR-32 human neuriblastoma xenografts (6–12 mm) were treated intralesionally with live NDV, UV-inacivated NDV, or phosphate-buffered saline (PBS). To study vrius replication in situ, mice were given intraumoral or intramuscular injections of NDV. These mice were then killed at various times, and the amount of infectious viurs present in tumor or muscle was determined.Results: after one injection of live NDV, 17 of 18 tumorsregressed completely, Whereas rapid tumor growth occured in all 18 mice treated with PBS and in all nine mice treated with UV-inactivated NDV (P<.0001). The one tumor that showed only a partial response to asingle injection regressed completely after a second NDV treatment, six months following virus-induced regression, only one tumor had recurred.Nosignificant acute or chronic side effects of live NDV were noted in athymic mice given doses up to 500 times that used in this study. Virus levels increased more than 80-fold between 5 and 24 hours in virus-injected tumors(P<.04), while no infectious virus was produced in NDV-injected muscle tissue. Conclusions: NDv 73-T appears to replcate selectively in human IMR-32 neuroblastoma xenografts, leading directly to a potent antitumor effect as demonstrated by long-lasting, complete tumor regression occuring after a single local injection of virus. Implication: These experiments may proveide an important step in the development af new therapeutic approaches to challenging cancers such as neuroblastoma. [J Natl Cancer Inst 86: 1228–1233, 1994]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. D. Gainey, M. J. Manuse, and G. D. Parks A Hyperfusogenic F Protein Enhances the Oncolytic Potency of a Paramyxovirus Simian Virus 5 P/V Mutant without Compromising Sensitivity to Type I Interferon J. Virol., October 1, 2008; 82(19): 9369 - 9380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Fabian, C. M. Csatary, J. Szeberenyi, and L. K. Csatary p53-Independent Endoplasmic Reticulum Stress-Mediated Cytotoxicity of a Newcastle Disease Virus Strain in Tumor Cell Lines J. Virol., March 15, 2007; 81(6): 2817 - 2830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Elankumaran, D. Rockemann, and S. K. Samal Newcastle Disease Virus Exerts Oncolysis by both Intrinsic and Extrinsic Caspase-Dependent Pathways of Cell Death J. Virol., August 1, 2006; 80(15): 7522 - 7534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Pecora, N. Rizvi, G. I. Cohen, N. J. Meropol, D. Sterman, J. L. Marshall, S. Goldberg, P. Gross, J. D. O'Neil, W. S. Groene, et al. Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers J. Clin. Oncol., May 1, 2002; 20(9): 2251 - 2266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Mullen and K. K. Tanabe Viral Oncolysis Oncologist, April 1, 2002; 7(2): 106 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Ansardi, D. C. Porter, C. A. Jackson, G. Y. Gillespie, and C. D. Morrow RNA Replicons Derived from Poliovirus Are Directly Oncolytic for Human Tumor Cells of Diverse Origins Cancer Res., December 1, 2001; 61(23): 8470 - 8479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Grote, S. J. Russell, T. I. Cornu, R. Cattaneo, R. Vile, G. A. Poland, and A. K. Fielding Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice Blood, June 15, 2001; 97(12): 3746 - 3754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ikeda, H. Wakimoto, T. Ichikawa, S. Jhung, F. H. Hochberg, D. N. Louis, and E. A. Chiocca Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant J. Virol., May 15, 2000; 74(10): 4765 - 4775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. Csatary and T. Bakacs Use of Newcastle Disease Virus Vaccine (MTH-68/H) in a Patient With High-grade Glioblastoma JAMA, May 5, 1999; 281(17): 1588 - 1589. [Full Text] [PDF]
|
|